Project Grant R21AI202073
Award Date 8/17/26
Completion Date 7/31/28
Dollars Obligated $228K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Athens, GA 30602, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded The Trustees of Columbia University in the City of New York $214,906 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop nanobodies as immunotherapy against invasive aspergillosis. The project addresses therapeutic limitations in treating invasive aspergillosis, a devastating infection with mortality rates exceeding 50% in immunocompromised populations despite three classes of...
- The National Institute of Allergy and Infectious Diseases awarded $400,932 to the University of Georgia Research Foundation, Inc. on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research into immunity induced by cryptococcal morphological strains in CD4+ T cell-deficient hosts. The research addresses cryptococcal meningoencephalitis, which accounts for more than 15 percent of total AIDS-related deaths globally, with mortality rates...
- The National Institute of Allergy and Infectious Diseases awarded the University of Georgia Research Foundation $1,023,862 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to produce and distribute filarial research reagents through the Filariasis Research Reagent Resource Center (FR3). The award funds three specific aims over a five-year period ending August 31, 2031. Under Aim 1, the recipient will ensure continued provision of high-quality...
- The National Institute of Allergy and Infectious Diseases awarded the University of Georgia Research Foundation $228,000 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop enzymatic pipelines for the in vitro synthesis of parasitic glycosylphosphatidylinositol (GPI) anchors and GPI-anchored proteins. Parasitic infections affect more than one billion people globally. GPI anchors and GPI-anchored proteins are essential to parasite cell surfaces and...
- The National Institute of Allergy and Infectious Diseases awarded the University of Georgia Research Foundation, Inc. $759,935 on July 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and evaluate the NXT-2 pan-fungal vaccine candidate targeting recurrent vulvovaginal candidiasis. The award funds evaluation of NXT-2, a recombinant consensus peptide based on highly conserved fungal protein sequences, in a novel non-human primate model of recurrent...
- The National Institute of Allergy and Infectious Diseases awarded the University of Wisconsin–Madison $213,811 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop chimeric antigen receptor-engineered neutrophils as a therapeutic for Aspergillus fumigatus infection. The award funds research to engineer induced pluripotent stem cell-derived neutrophils armed with anti-Aspergillus CARs to overcome the limited efficacy of conventional antifungal agents...
- The National Institute of Allergy and Infectious Diseases awarded the University of Georgia Research Foundation, Inc. $264,633 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to optimize antivirals against poxviruses. The funded work advances preclinical development of modified carbocyclic nucleoside analogs targeting monkeypox virus (MPXV) and vaccinia virus (VACV). The research team identified a lead compound demonstrating potency of 187 nanomolar...
- The National Institute of Allergy and Infectious Diseases awarded the University of Tennessee Health Science Center $163,852 on November 1, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on the septation initiation network (SIN) kinase cascade in Aspergillus fumigatus, with the goal of enhancing echinocandin antifungal efficacy against invasive pulmonary aspergillosis. The research interrogates SIDB-dependent septation mechanisms that confer...
- The National Institute of Allergy and Infectious Diseases awarded Clemson University $418,378 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of long-noncoding RNA AFU-182 in regulating fungal tolerance to azole antifungal drugs in Aspergillus fumigatus. The research addresses rising invasive infections caused by the saprophytic mold A. fumigatus and the unclear mechanisms of fungal adaptation to azole drugs. The project will...
- The National Institute of Allergy and Infectious Diseases awarded the University of Tennessee Health Science Center $678,934 on July 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate novel host-adaptation mechanisms regulating Aspergillus fumigatus pathogenic fitness in invasive aspergillosis. The recipient will conduct basic science research identifying and characterizing new antifungal targets for invasive mold infection caused by A. fumigatus,...